{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:32Z","timestamp":1791612452223,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["19172MFDS170"],"award-info":[{"award-number":["19172MFDS170"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.semarthrit.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T13:09:01Z","timestamp":1625749741000},"page":"989-995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea"],"prefix":"10.1016","volume":"51","author":[{"given":"Ha-Lim","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14712598.2017.1346078","article-title":"Safety profile of biological therapies for treating rheumatoid arthritis","volume":"17","author":"Canete","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1759720X18798462","article-title":"New insights and long-term safety of tocilizumab in rheumatoid arthritis","volume":"10","author":"Jones","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0003","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11926-016-0609-5","article-title":"Infections with biologics in rheumatoid arthritis and related conditions: a scoping review of serious or hospitalized infections in observational studies","volume":"18","author":"Singh","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0005","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis","volume":"5","author":"Singh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0006","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis","volume":"3","author":"Singh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0007","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0009","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford, England)."},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","article-title":"Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry","volume":"17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0012","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0013","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0014","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gron","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthr Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0016","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S1473-3099(17)30623-0","article-title":"Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives","volume":"18","author":"Abel","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","article-title":"The changing epidemiology of liver diseases in the Asia-Pacific region","volume":"16","author":"Wong","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0018","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/apt.14561","article-title":"Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection","volume":"47","author":"Zamani","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0019","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","article-title":"Development of an algorithm for identifying rheumatoid arthritis in the Korean national health insurance claims database","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0020","first-page":"h2809","article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pds.2074","article-title":"The role of the c-statistic in variable selection for propensity score models","volume":"20","author":"Westreich","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0022","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0024","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0025","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0026","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kwv445","article-title":"Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies","volume":"184","author":"Karim","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0028","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0029","unstructured":"OECD. Doctors' consultations (indicator). 2020."},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","article-title":"Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study","volume":"59","author":"Gr\u00f8n","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0031","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1073\/pnas.89.11.5068","article-title":"Interleukin 6: insights to its function in skin by overexpression in transgenic mice","volume":"89","author":"Turksen","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0032","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0033","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 differs from TNF-\u03b1: unpredicted clinical effects caused by IL-6 blockade in psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2021.07.004_bib0034","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/infdis\/jiu159","article-title":"Sex differences in infectious diseases-common but neglected","volume":"209","author":"van Lunzen","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006688","article-title":"Sex differences shape the response to infectious diseases","volume":"13","author":"Ingersoll","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0036","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semarthrit.2021.07.004_bib0037","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:05:47Z","timestamp":1758733547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0049017221001293"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.07.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}